Tryn Stimart - 07 Jun 2021 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role: Chief Legal Officer
Signature: /s/ Tryn Stimart
Issuer symbol: ABCL
Transactions as of: 07 Jun 2021
Net transactions value: +$815,000
Form type: 4
Filing time: 09 Jun 2021, 20:30:37 UTC
Next filing: 10 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABCL	Common Shares	Options Exercise	$240,000	+750,000	+300000%	$0.3200^*	750,250	07 Jun 2021	Direct
transaction	ABCL	Common Shares	Options Exercise	$575,000	+250,000	+33%	$2.30	1,000,250	07 Jun 2021	Direct
holding	ABCL	Common Shares						250	07 Jun 2021	By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABCL	Share Option (right to buy)	Options Exercise	$0	-750,000	-38%	$0.000000	1,250,000	07 Jun 2021	Common Shares	750,000	$0.3200	Direct	F1, F2
transaction	ABCL	Share Option (right to buy)	Options Exercise	$0	-250,000	-29%	$0.000000	600,000	07 Jun 2021	Common Shares	250,000	$2.30	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Previously reported on Form 3 filed on December 11, 2020. The vesting schedule was amended as follow: 25% of the shares subject to such option vest and become exercisable on August 22, 2020; 6.25% of the shares subject to such option vest and become exercisable on November 22, 2020 and February 22, 2021; 4.70% of the shares subject to such option vest and become exercisable on on July 1, 2022; 8.9% of the shares subject to such option vest and become exercisable on October 1, 2022; 7.4% of the shares subject to such option vest and become exercisable on January 1, 2023; 10.40% of the shares subject to such option vest and become exercisable on April 1, 2023; 8.90% of the shares subject to such option vest and become exercisable on July 1, 2023 and October 1, 2023; 2.70% of the shares subject to such option vest and become exercisable on January 1, 2024;
F2	(Continued from footnote 1) and 2.65% of the shares subject to such option vest and become exercisable on April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025.
F3	Previously reported on Form 3 filed on December 11, 2020 and Form 4 filed on December 17, 2020. The vesting schedule was amended such that all of the shares subject to such option were vested as of March 24, 2021.